The present invention concerns: a plant growth-promoting agent comprising a compound represented by Formula (I) or a salt thereof:

##STR00001##

wherein Ar.sup.1 represents a substituted or unsubstituted phenyl group, NZ represents a nitrogen-containing heterocyclic ring group or an acyclic nitrogen-containing group having a partial structure of the nitrogen-containing heterocyclic ring group, n is 0, 1, or 2, R.sup.1 and R.sup.2 each represent a hydrogen atom, a substituted or unsubstituted C.sub.1-3-alkyl group, a cyano group, or a carboxyl group, R.sup.1 and R.sup.2 may together form an oxo group, and when n is 2, R.sup.1 or R.sup.2 may be the same or different; and a method for promoting plant growth using the plant growth-promoting agent.

The present invention concerns: a plant growth-promoting agent comprising a compound represented by Formula (I) or a salt thereof:

##STR00001##

wherein Ar.sup.1 represents a substituted or unsubstituted phenyl group, NZ represents a nitrogen-containing heterocyclic ring group or an acyclic nitrogen-containing group having a partial structure of the nitrogen-containing heterocyclic ring group, n is 0, 1, or 2, R.sup.1 and R.sup.2 each represent a hydrogen atom, a substituted or unsubstituted C.sub.1-3-alkyl group, a cyano group, or a carboxyl group, R.sup.1 and R.sup.2 may together form an oxo group, and when n is 2, R.sup.1 or R.sup.2 may be the same or different; and a method for promoting plant growth using the plant growth-promoting agent.

The present invention relates to novel compounds as HIF-1α inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1α, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1α-mediated VEGFA expression.

The present invention relates to novel compounds as HIF-1α inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1α, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1α-mediated VEGFA expression.

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. ##STR00001##

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. ##STR00001##

Shown and described are improved processes for the preparation of dapagliflozin of Formula I, ##STR00001##
or its solvates or co-crystals thereof and intermediates and their use in the preparation of dapagliflozin of Formula I or its solvates or co-crystals thereof.

The present invention is directed to 1,4-disubstituted piperidines, 1,4-disubstituted piperazines, 1,4-disubstituted diazepanes, and 1,3-disubstituted pyrrolidine compounds and their use.

The present invention is directed to 1,4-disubstituted piperidines, 1,4-disubstituted piperazines, 1,4-disubstituted diazepanes, and 1,3-disubstituted pyrrolidine compounds and their use.

The present invention relates to air stable, binary Ni(0)-olefin complexes and their use in organic synthesis.